Pharmadrug Inc. (TSE:PHRX) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
PharmaDrug’s subsidiary Sairiyo Therapeutics has wrapped up the clinical and regulatory preparations necessary for a Phase 1 study in Australia, targeting the use of PD-001, a reformulated version of cepharanthine, for infectious diseases and cancer treatment. The company is poised to submit for ethical approval and looks forward to benefitting from Australia’s R&D tax incentives, with an eye on future FDA trials in the United States. PD-001 offers improved oral bioavailability over traditional cepharanthine, potentially enhancing therapeutic outcomes for patients.
For further insights into TSE:PHRX stock, check out TipRanks’ Stock Analysis page.